MX2020011367A - Compuesto oxo-sustituido. - Google Patents

Compuesto oxo-sustituido.

Info

Publication number
MX2020011367A
MX2020011367A MX2020011367A MX2020011367A MX2020011367A MX 2020011367 A MX2020011367 A MX 2020011367A MX 2020011367 A MX2020011367 A MX 2020011367A MX 2020011367 A MX2020011367 A MX 2020011367A MX 2020011367 A MX2020011367 A MX 2020011367A
Authority
MX
Mexico
Prior art keywords
compound
preventive
oxo
inhibitory effect
lactamase
Prior art date
Application number
MX2020011367A
Other languages
English (en)
Spanish (es)
Inventor
Toshio Kanai
Toshiaki Sunazuka
Yoshihiko Noguchi
Sachiko Koike
Takayuki Fukaya
Shunichiro UESUGI
Shingo Mizushima
Hitoshi Suda
Yuki Mizukami
Yohei Ikuma
Original Assignee
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68295570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020011367(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sumitomo Pharma Co Ltd filed Critical Sumitomo Pharma Co Ltd
Publication of MX2020011367A publication Critical patent/MX2020011367A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2020011367A 2018-04-27 2019-04-26 Compuesto oxo-sustituido. MX2020011367A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018087761 2018-04-27
PCT/JP2019/018011 WO2019208797A1 (ja) 2018-04-27 2019-04-26 オキソ置換化合物

Publications (1)

Publication Number Publication Date
MX2020011367A true MX2020011367A (es) 2021-02-09

Family

ID=68295570

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011367A MX2020011367A (es) 2018-04-27 2019-04-26 Compuesto oxo-sustituido.

Country Status (15)

Country Link
US (3) US11702431B2 (cg-RX-API-DMAC10.html)
EP (1) EP3786168A4 (cg-RX-API-DMAC10.html)
JP (2) JP7360132B2 (cg-RX-API-DMAC10.html)
KR (1) KR102679411B1 (cg-RX-API-DMAC10.html)
CN (2) CN112135830B (cg-RX-API-DMAC10.html)
AU (1) AU2019259818B2 (cg-RX-API-DMAC10.html)
CA (1) CA3098433A1 (cg-RX-API-DMAC10.html)
EA (1) EA202092579A1 (cg-RX-API-DMAC10.html)
IL (1) IL278262B2 (cg-RX-API-DMAC10.html)
MX (1) MX2020011367A (cg-RX-API-DMAC10.html)
PH (1) PH12020551772A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202010661SA (cg-RX-API-DMAC10.html)
TW (2) TWI829686B (cg-RX-API-DMAC10.html)
UA (1) UA129150C2 (cg-RX-API-DMAC10.html)
WO (1) WO2019208797A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2020138499A1 (ja) * 2018-12-28 2021-11-04 大日本住友製薬株式会社 アルキル置換化合物
US20230038124A1 (en) * 2019-10-25 2023-02-09 Sumitomo Pharma Co., Ltd. Novel substituted condensed ring compound
US11476003B2 (en) * 2020-12-15 2022-10-18 Biodesix, Inc. Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings
JPWO2024128238A1 (cg-RX-API-DMAC10.html) 2022-12-13 2024-06-20

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201000774A1 (ru) * 2007-11-13 2010-12-30 Новартис Интернэшнл Фармасьютикл Лтд. Ингибиторы бета-лактамазы
JP6403219B2 (ja) 2012-12-07 2018-10-10 ベナトルクス ファーマシューティカルズ,インク. ベータ−ラクタマーゼ阻害剤
KR20150103270A (ko) * 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
AU2014204045B2 (en) 2013-01-04 2018-10-18 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN105101970B (zh) 2013-01-10 2018-11-20 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
AU2015264418A1 (en) * 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR102396753B1 (ko) 2014-06-11 2022-05-12 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
AU2015284307A1 (en) 2014-07-01 2017-02-02 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3347008B1 (en) 2015-09-11 2022-03-09 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors

Also Published As

Publication number Publication date
CA3098433A1 (en) 2019-10-31
IL278262B2 (en) 2025-04-01
JP7598594B2 (ja) 2024-12-12
CN112135830A (zh) 2020-12-25
JPWO2019208797A1 (ja) 2021-05-27
KR102679411B1 (ko) 2024-07-01
TWI915735B (zh) 2026-02-21
SG11202010661SA (en) 2020-11-27
TWI829686B (zh) 2024-01-21
EP3786168A4 (en) 2022-03-23
EA202092579A1 (ru) 2021-04-01
BR112020021631A2 (pt) 2021-01-26
CN118638140A (zh) 2024-09-13
US11702431B2 (en) 2023-07-18
TW201945006A (zh) 2019-12-01
PH12020551772A1 (en) 2021-07-12
AU2019259818A1 (en) 2020-11-26
IL278262A (en) 2020-12-31
JP7360132B2 (ja) 2023-10-12
EP3786168A1 (en) 2021-03-03
US20230287009A1 (en) 2023-09-14
UA129150C2 (uk) 2025-01-29
WO2019208797A1 (ja) 2019-10-31
IL278262B1 (en) 2024-12-01
US20210147448A1 (en) 2021-05-20
JP2023168413A (ja) 2023-11-24
BR112020021631A8 (pt) 2023-02-28
US11066425B1 (en) 2021-07-20
CN112135830B (zh) 2024-06-14
AU2019259818B2 (en) 2023-06-01
TW202421162A (zh) 2024-06-01
KR20210005910A (ko) 2021-01-15

Similar Documents

Publication Publication Date Title
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CO2019002556A2 (es) Composición farmacéutica
CO2022008968A2 (es) Nuevos derivados de metilquinazolinona
AR112271A1 (es) Composiciones que comprenden un inhibidor de arn polimerasa y ciclodextrina para el tratamiento de infecciones virales
MX2023002233A (es) Compuestos fosfolipidos y usos de estos.
DOP2025000244A (es) Compuestos y métodos para el tratamiento de infecciones virales
MX2020007947A (es) Inhibidores de erbb/btk.
MX2024009926A (es) Composiciones y metodos para tratar trastornos del snc.
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
PH12020551772A1 (en) Oxo-substituted compound
CL2022001353A1 (es) Inhibidores de egfr
DOP2022000076A (es) Inhibidores del factor d del complemento para administración oral
AR121598A1 (es) Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano
PH12022550983A1 (en) Novel substituted condensed ring compound
AR132764A1 (es) Inhibidores de tyk2 y sus usos
MX2024010671A (es) Compuestos antivirales y metodos de elaboracion y uso de los mismos.
ECSP23080267A (es) Compuestos de lactivicina, su preparación y uso como agentes antibacterianos
CO2024012000A2 (es) Compuestos antivirales y métodos de elaboración y uso de los mismos
AR118141A1 (es) Compuestos para el tratamiento, alivio o prevención de trastornos asociados con los agregados de tau
AR126393A1 (es) Terapia combinada para el tratamiento de enfermedades hepáticas
AR131842A1 (es) Métodos para tratar gliomas
AR083780A1 (es) Composicion farmaceutica para tratar infecciones del hcv
MX2022000729A (es) Terapia de combinacion para el tratamiento del cancer.
AR134205A1 (es) Inhibidores de ripk1 y métodos de uso
CL2025001435A1 (es) Compuestos inhibidores de ddr1 para tratar cáncer.